Navigation Links
ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop

KOS, Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today the presentation of two posters at the XIth Annual International Myeloma Workshop being held in Kos, Greece from June 25-28th, 2007. The meeting highlights important advances made in the biology and treatment of multiple myeloma. ZIOPHARM is presenting darinaparsin (ZIO-101) gene expression profiling data that further elucidates its unique mechanism of action as well as interim Phase II data from two ongoing trials in advanced myeloma.

The first poster, presented on Tuesday June 26th by Larry Boise, PhD from the Sylvester Comprehensive Cancer Center at the University of Miami highlighted preclinical data demonstrating darinaparsin (ZIO-101) may have activity in myeloma patients who have already been treated with and no longer respond to arsenic trioxide.

The second poster, presented today by James R. Berenson, M.D., Berenson Oncology, Inc., West Hollywood, CA, and principal investigator, reiterates interim phase II data from two ongoing studies recently presented at the American Society of Clinical Oncology (ASCO) Meeting in Chicago. The two ongoing phase II studies are evaluating the preliminary efficacy and safety profile of different treatment schedules (5 consecutive days every four weeks; twice weekly for 3 weeks, every four weeks) in patients with advanced/progressive myeloma (patients to date have had a median of 7 prior therapies). As reported, of the 14 patients treated 5 consecutive days, there are 10 patients evaluable for efficacy, with 4 out of the 10 (40%) achieving stable disease greater than 4 months duration. Data from the twice weekly study is not yet evaluable (3 patients treated). Darinaparsin has been well tolerated and no clinically relevant QT prolongation, bone marrow suppression or neuropathy has been observed with either treatment schedule.

"With the passage of time it bec
'"/>




Page: 1 2 3 4

Related medicine technology :

1. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:7/3/2015)... July 3, 2015  Obsidian HDS, the developer of ... service for the management of data on pharmaceutical and ... PharmaShine now includes the 2014 Open Payments General and ... on June 30. The data disclosed on Open Payments ... industry and providers totaling $6.49 billion and is the ...
(Date:7/2/2015)... , July 2, 2015 /PRNewswire/ - ESSA Pharma Inc. ... common shares have been approved for listing and trading on ... ESSA will begin trading on NASDAQ on July 9, ... Venture Exchange under the symbol "EPI". As a ... NASDAQ, each of the Company,s outstanding special warrants issued on ...
(Date:7/2/2015)... -- Releases of the genetically engineered Oxitec ... , , reduced the dengue mosquito population in an ... 95%, well below the modelled threshold for epidemic disease ... The journal PLOS Neglected Tropical Diseases published today the ... The results showed that in Juazeiro city, northeast ...
Breaking Medicine Technology:New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3
... , HARBIN, China, Nov. 17 /PRNewswire-Asia-FirstCall/ ... Company") (Nasdaq: CSKI ), a,leading fully integrated pharmaceutical company in ... the third quarter,of 2009. , , Third Quarter ... to $43.2 million, -- Gross profit increased 44.8% ...
... Mass., Nov. 17 Decision Resources, one of the world,s ... finds that, driven by the continued dominance of opioids that ... cancer pain drug market will increase from $2.3 billion in ... France, Germany, Italy, Spain, the United Kingdom and Japan. , ...
Cached Medicine Technology:China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 2China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 3China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 4China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 5China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 6China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 7China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 8China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 9China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 10The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2
(Date:7/3/2015)... ... July 03, 2015 , ... ... 2015 Annual Conference , the premiere continuing education and networking event ... at SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts in ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... took place on June 25, 2015 at 1:00pm. The Association welcomed speaker C. ... pertaining to injured bicyclists and practical points of investigating these types of cases. ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ... the latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert ... selfie sticks are great for documenting memories. , Almost every smartphone has an incredibly ...
(Date:7/2/2015)... ... ... Enterprises, LLC. is pleased to announce the opening of its newest location in Dallas, Texas. ... premium frozen yogurt chain was listed as #22 on the Inc. 500 list of fastest ... Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , ...
(Date:7/2/2015)... RI (PRWEB) , ... July 02, 2015 , ... Many ... safety in mind. That’s why Amica Insurance is sharing some tips to ... Commission (CPSC), approximately 230 people go to the emergency room daily with fireworks-related injuries ...
Breaking Medicine News(10 mins):Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:6 Fireworks Safety Tips from Amica Insurance 2
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... called infective endocarditis, coupled with heart failure, heart valve surgery ... new study suggests. Infective endocarditis, an infection of ... valves, has been associated with a high risk of death. ...
... , TUESDAY, Nov. 22 (HealthDay News) -- ,Taking slightly ... the brand name Tylenol) over time can lead to an ... a new study. These "staggered overdoses" can occur when ... acetaminophen than they should, explained Dr. Kenneth Simpson, author of ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... "energy" drinks skyrockets, so do related health problems, a ... almost 10 times more cases of reactions to beverages such ... to a new U.S. government report released Tuesday. More ...
... , TUESDAY, Nov. 22 (HealthDay News) -- Elderly black ... are much more likely to die in the hospital than ... risk of death was present even when black patients had ... researchers found. Diverticulitis occurs when small pouches in the ...
... discovered the novel protective role dendritic cells play in ... issue of journal Gastroenterology , shows dendritic cells ... dangerous swelling and inflammation of the pancreas gland. ... dendritic cells are needed in the pancreas for normal, ...
... News) --,College students tend to smoke when they are partying, ... are using social events and work as cues to remind ... an assistant professor of family and community medicine at the ... "This research is important for those working with college students ...
Cached Medicine News:Health News:Surgery May Boost Survival With Dangerous Heart Condition 2Health News:Surgery May Boost Survival With Dangerous Heart Condition 3Health News:Too Much Acetaminophen Over Time May Damage Liver 2Health News:ER Visits for Energy-Drink Ills Soar in U.S. 2Health News:ER Visits for Energy-Drink Ills Soar in U.S. 3Health News:More Blacks Die in Hospital After Diverticulitis Surgery 2Health News:Dendritic cells protect against acute pancreatitis 2Health News:Dendritic cells protect against acute pancreatitis 3Health News:College Students Smoke When They Party, Drink and Work 2
... A lower cost alternative to Equalizers, the patented ... between two different vessel configurations. With the push ... be quickly and easily adjusted for test tubes ... Ergonomic Design for Unparalleled Comfort Pick one ...
... Exp Expandable Tip System A lower cost ... you to perform multi-sample transfers between two different ... a knob, tip spacing can be quickly and ... or 96 well plates. Ergonomic Design for ...
... Exp Expandable Tip System A ... System allows you to perform multi-sample transfers between ... pull of a knob, tip spacing can be ... microcentrifuge tubes) or 96 well plates. Ergonomic ...
... Expandable Tip System A lower cost alternative ... to perform multi-sample transfers between two different vessel ... knob, tip spacing can be quickly and easily ... 96 well plates. Ergonomic Design for Unparalleled ...
Medicine Products: